Chemical compound
Pharmaceutical compound
Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]
It was approved by the Food and Drug Administration in 2000.[3]In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]
In 2015, the drug was discontinued in the U.S.[citation needed]
References
- ^ Micromedex Detailed Consumer Information
- ^ Fung DS, Whitson JT (2014). “An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy”. Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
- ^ “Drug Approval Package”. Food and Drug Administration.
- ^ “Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada” (Press release). Business Wire. April 24, 2009.
| Precursor | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostanoids |
| ||||||||||||||
| Leukotrienes (LT) |
| ||||||||||||||
| Eoxins (EX) |
| ||||||||||||||
| Nonclassic |
| ||||||||||||||
| By function | |||||||||||||||
| Receptor (ligands) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
| Others | |||||||||||||||||||||||||||